Nuveen
COAG icon

Nuveen’s Hemab Therapeutics COAG Stock Holding History

Nuveen’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$906K Buy
+29,387
New +$1.29M ﹤0.01% 3051

Other funds holding COAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Nuveen's COAG Position: Q3 2026 in Review

Nuveen opened a new position in Hemab Therapeutics (COAG) in Q3 2026: 29,387 shares worth $906K. The stake represents ﹤0.01% of the portfolio and ranks #3051 among its holdings.

20 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • Nuveen held 29,387 shares of Hemab Therapeutics worth $906K as of Q3 2026.
  • Hemab Therapeutics was a new Nuveen position in Q3 2026.
  • Hemab Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3051 holding.
  • 20 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.